Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD
Public ClinicalTrials.gov record NCT02022540. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Open-Label, Multi-Center Trial With Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with active, subfoveal choroidal neovascularization associated with neovascular Age-Related Macular Degeneration (AMD).
Study identification
- NCT ID
- NCT02022540
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 50 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2014 (Type not available)
- Primary completion
- Mar 2016 (Actual)
- Completion
- May 2016 (Actual)
- Last update posted
- Sep 28, 2016
2014 – 2016
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Colorado Springs | Colorado | — | — |
| Not listed | Winter Haven | Florida | — | — |
| Not listed | Shawnee Mission | Kansas | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Portsmouth | New Hampshire | — | — |
| Not listed | Bloomfield | New Jersey | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Statesville | North Carolina | — | — |
| Not listed | Ashland | Oregon | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | West Columbia | South Carolina | — | — |
| Not listed | Rapid City | South Dakota | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Abilene | Texas | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Harlingen | Texas | — | — |
| Not listed | McAllen | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Willow Park | Texas | — | — |
| Not listed | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02022540, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2016 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02022540 live on ClinicalTrials.gov.